Business Context and Reporting Period
Company: MESA LABORATORIES INC
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Mesa Laboratories manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2011 (Ended June 30, 2010) | Q1 2010 (Ended June 30, 2009) |
|---|---|---|
| Net Sales | $7,455,000 | $4,977,000 |
| Gross Profit | $4,381,000 | $2,983,000 |
| Gross Margin | 59% | 60% |
| Operating Income | $2,214,000 | $1,608,000 |
| Net Income | $1,320,000 | $1,026,000 |
| Diluted EPS | $0.40 | $0.31 |
| Cash and Equivalents | $2,541,000 | $10,759,000 |
| Total Debt (Current + Long Term) | $4,571,000 | $100,000 |
| Working Capital | $8,769,000 | $18,005,000 |
| Current Ratio | 2.7:1 | 13:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 50% ($2.478 million) year-over-year. This was driven by internal growth and the acquisition of SGM Biotech (April 2010) and Torqo (December 2009). SGM Biotech contributed $1.653 million and Torqo contributed $459,000 to the increase.
- Profitability: Net income increased 29% to $1.32 million. However, gross margin decreased 1.1 percentage points to 59% due to a shift in product mix toward lower-margin Biological Indicator products (SGM) and Torqo products (outsourced manufacturing).
- Liquidity and Debt: Cash and cash equivalents decreased by $7.93 million, primarily due to the $12.027 million acquisition of SGM Biotech and $2.15 million facility purchase. To finance these, the company took on $4.571 million in new debt (a $3 million term loan and a $1.521 million draw on a revolving line of credit), compared to minimal debt in the prior year.
- Balance Sheet: Total assets increased from $33.6 million to $42.6 million, driven by a significant increase in Goodwill and Intangibles ($21.1 million vs $8.9 million) and Property, Plant & Equipment ($7.5 million vs $4.2 million).
Guidance, Outlook, and Risks
- Outlook: Management expects capital spending trends to improve in domestic and international markets for the remainder of fiscal 2011. They anticipate higher general and administrative costs and amortization expenses in fiscal 2011 due to the SGM acquisition.
- Margin Expectations: Gross margins are expected to remain under pressure until Torqo manufacturing operations are brought in-house by the end of calendar 2010. The effective tax rate is expected to be higher in fiscal 2011 due to non-deductible amortization of acquired intangible assets.
- Capital Allocation: The company is minimizing stock buybacks due to lower cash and higher debt positions. Surplus cash flow will be used to fund dividends and retire debt.
- Risks: Key risks include general economic conditions, competition in data logging and medical markets, and the impact of unusual items from business strategy evaluations. The company notes that forward-looking statements are subject to these uncertainties.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and the timeline for bringing Torqo manufacturing in-house to improve margins.
- Debt Servicing: Monitor the company's ability to service the new $4.571 million debt load, specifically the quarterly principal payments of $250,000 on the term loan.
- Working Capital Adjustment: Confirm the final working capital adjustment for the SGM Biotech acquisition, currently accrued at $305,000.
- Product Mix: Track the sales mix between high-margin legacy products (Medical/Datatrace) and lower-margin acquired products (SGM/Torqo) to assess long-term margin recovery.
- Cash Flow: Review future operating cash flows to ensure they remain sufficient to cover debt obligations and dividend payments without further dilution or asset sales.